Hikal Ltd.
Snapshot View

358.00 -9.60 ▼-2.6%

27 January 2023, 04:01:00 PM
Volume: 67,905

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.hikal.com
Market Cap 4,438.21 Cr.
Enterprise Value(EV) 5,139.37 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 6.64 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 53.90 Trailing Twelve Months Ending 2022-09
Industry PE 32.90 Trailing Twelve Months Ending 2022-09
Book Value / Share 87.56 Trailing Twelve Months Ending 2022-09
Price to Book Value 4.09 Calculated using Price: 358.00
Dividend Yield 0.44 Period Ending 2022-03
No. of Shares Subscribed 12.33 Cr. 123,300,750 Shares
FaceValue 2
Company Profile
Established in 1988 Hikal is a reliable partner to companies in the Pharmaceuticals, Biotech, Agrochemicals and Specialty Chemicals industries. They provide world-class Active Ingredients, Intermediates and R&D services and solutions in a safe, secure and confidential manner. Their advanced infrastructure has been inspected and approved by globally recognized bodies such as the USFDA.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-2.61%
1 Week
-7.54%
1 Month
-0.32%
3 Month
+8.78%
6 Month
+44.76%
1 Year
-5.22%
2 Year
+109.42%
5 Year
+136.66%
10 Year
+520.24%
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 17.27 9.81 9.32 12.74 12.12 14.46 10.74 15.22 16.04
Return on Capital Employed (%) 17.77 12.50 11.92 11.87 12.81 15.25 12.44 16.15 15.21
Return on Assets (%) 5.17 3.12 3.17 5.02 5.15 6.11 4.62 6.84 7.39

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 505 532 564 605 669 756 817 933 1,068 1,080
Non Curr. Liab. 298 242 337 324 312 359 410 379 432 427
Curr. Liab. 479 530 397 470 616 659 653 703 828 812
Minority Int.
Equity & Liab. 1,282 1,304 1,298 1,400 1,597 1,775 1,879 2,016 2,328 2,319
Non Curr. Assets 775 791 808 793 851 888 1,048 1,091 1,305 1,333
Curr. Assets 507 513 490 607 746 886 831 925 1,023 986
Misc. Exp. not W/O
Total Assets 1,282 1,304 1,298 1,400 1,597 1,775 1,879 2,016 2,328 2,319

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 829 872 926 1,014 1,296 1,590 1,507 1,720 1,943 1,954
Other Income 34 2 2 3 4 2 4 5 5 5
Total Income 863 873 927 1,017 1,301 1,592 1,511 1,725 1,948 1,960
Total Expenditure -642 -689 -745 -815 -1,054 -1,291 -1,234 -1,398 -1,602 -1,708
PBIDT 221 184 183 202 246 300 277 328 345 252
Interest -68 -60 -62 -48 -49 -58 -52 -36 -31 -37
Depreciation -55 -64 -67 -69 -86 -93 -82 -85 -96 -103
Taxation -34 -19 -12 -13 -34 -46 -42 -73 -58 -30
Exceptional Items -4 -15
PAT 64 40 41 68 77 103 84 133 161 82
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 64 40 41 68 77 103 84 133 161 82
Adjusted EPS 5 3 3 5 6 8 7 11 13 7

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 61 154 102 186 163 139 186 285 229 294
Cash Fr. Inv. -28 -23 -43 -64 -102 -110 -125 -164 -156 -284
Cash Fr. Finan. -27 -124 -69 -124 -63 -25 -55 -101 -97 -6
Net Change 6 7 -10 -2 -2 4 6 20 -24 4
Cash & Cash Eqvt 9 16 6 4 2 6 11 32 8 11

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 68.77 68.77 68.77 68.77 68.77 68.77 68.77 68.77 68.83
Public 31.23 31.23 31.23 31.23 31.23 31.23 31.23 31.23 31.17
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Wed, 25 Jan 2023
Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results For The Quarter And Period Ended December 31 2022 And Interim Dividend
HIKAL LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2023 inter alia to consider and approve a. Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and period ended December 31 2022; and b. to consider payment of interim dividend if any on the equity shares of the Company for the financial year 2022-23.
Wed, 25 Jan 2023
Corporate Action-Board to consider Dividend
Board is to consider payment of interim dividend if any on the equity shares of the Company for the financial year 2022-23.
Tue, 17 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2022

Technical Scans View Details >>

Fri, 27 Jan 2023
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Closing Below Previous Low Closing Below Previous Low
Closing Below Previous Low for 3 days Closing Below Previous Low for 3 days

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 249,710.79 1,040.75 +0.1%
Divi's Laboratories Ltd. 89,875.72 3,385.55 +1.5%
Cipla Ltd. 84,895.40 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. 71,960.69 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. 61,265.20 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. 52,047.83 1,537.85 -1.3%
Abbott India Ltd. 45,216.39 21,279.00 0.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 60.84 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 30.03 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-12 32.18 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 19.75 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.97 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.63 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-09 51.28 21,279.00 0.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.70 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 7.41 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-12 3.74 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.27 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.24 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.17 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-09 16.66 21,279.00 0.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 0.04 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 0.00 21,279.00 0.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 29.95 21,279.00 0.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 29.95 21,279.00 0.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 4,919.27 21,279.00 0.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 798.70 21,279.00 0.0%

FAQ's On Hikal Ltd.

What is Hikal share price?

Can I buy Hikal shares now?

What is the Dividend Yield of Hikal?

What is the Market Cap of Hikal?

What are the key metrics to analyse Hikal?

What is the 52 Week High and Low of Hikal?

What is the trend of Hikal share price?